- Home
- KALV vs IIIV Comparison
KALV vs IIIV Comparison
Compare KALV & IIIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- IIIV
- Stock Information
- Founded
- KALV N/A
- IIIV 2012
- Country
- KALV United States
- IIIV United States
- Employees
- KALV N/A
- IIIV 1663
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- IIIV EDP Services
- Sector
- KALV Health Care
- IIIV Technology
- Exchange
- KALV Nasdaq
- IIIV Nasdaq
- Market Cap
- KALV 642.3M
- IIIV 615.0M
- IPO Year
- KALV N/A
- IIIV 2018
- Fundamental
- Price
- KALV $11.25
- IIIV $27.47
- Analyst Decision
- KALV Strong Buy
- IIIV Buy
- Analyst Count
- KALV 8
- IIIV 7
- Target Price
- KALV $24.83
- IIIV $29.57
- AVG Volume (30 Days)
- KALV 1.1M
- IIIV 419.6K
- Earning Date
- KALV 07-10-2025
- IIIV 08-07-2025
- Dividend Yield
- KALV N/A
- IIIV N/A
- EPS Growth
- KALV N/A
- IIIV 4907.14
- EPS
- KALV N/A
- IIIV 4.75
- Revenue
- KALV N/A
- IIIV $241,651,000.00
- Revenue This Year
- KALV N/A
- IIIV N/A
- Revenue Next Year
- KALV N/A
- IIIV $5.74
- P/E Ratio
- KALV N/A
- IIIV $5.84
- Revenue Growth
- KALV N/A
- IIIV 5.59
- 52 Week Low
- KALV $7.30
- IIIV $20.42
- 52 Week High
- KALV $15.50
- IIIV $29.80
- Technical
- Relative Strength Index (RSI)
- KALV 35.75
- IIIV 64.54
- Support Level
- KALV $11.10
- IIIV $25.14
- Resistance Level
- KALV $12.17
- IIIV $27.87
- Average True Range (ATR)
- KALV 0.86
- IIIV 0.95
- MACD
- KALV -0.21
- IIIV 0.34
- Stochastic Oscillator
- KALV 30.34
- IIIV 92.35
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.